Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Udit Nindra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Background
The standard of care in newly diagnosed metastatic non‐small cell lung cancer (NSCLC) is to test for aberrations in three genes for driver mutations – ALK, ROS1 and epidermal growth factor receptor (EGFR) – and also for immunohistochemistry to be performed for programmed death‐ligand 1 expression level. Next‐generation sequencing (NGS), with or without RNA fusion testing, is increasingly used in standard clinical practice to identify patients with potentially actionable mutations. Stratification of NGS mutation tiers is currently based on the European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) Tiers I–V and X.
Aim
Our aim was to analyse NSCLC tumour samples for the prevalence of Tiers I–V mutations to establish guidance for current and novel treatments in patients with metastatic disease.
Methods
NGS was performed employing the Oncomine Precision Assay (without RNA fusion testing) that interrogates DNA hotspot variants across 45 genes to screen 210 NSCLC tissue samples obtained across six Sydney hospitals between June 2021 and March 2022.
Results
In our cohort, 161 of 210 (77%) had at least one gene mutation identified, with 41 of 210 (20%) having two or more concurrent mutations. Tier I mutations included 42 of 210 (20%) EGFR mutations (EIA) and five of 210 (3%) MET exon 14 skipping mutations (EIB). Non‐Tier I variants included 22 of 210 (11%) KRAS G12C hotspot mutations (EIIB), with a further 47 of 210 (22%) having non‐ G12C KRAS (EX) mutations. NGS testing revealed an additional 15% of cases with Tier II ESCAT mutations in NSCLC. Forty‐six percent of patients also demonstrated potential Tier III and IV mutations that are currently under investigation in early‐phase clinical trials.
Conclusions
In addition to identifying patients with genomic alterations suitable for clinically proven standard‐of‐care therapeutic options, the 45‐gene NGS panel has significant potential in identifying potentially actionable non‐Tier 1 mutations that may become future standard clinical practice in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia.
- Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, New South Wales, Australia.
- Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, New South Wales, Australia.
- Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
- Discipline of Pathology, School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
- South Western Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
ORCID-Profile: Udit Nindra, Abhijit Pal
Zitieren
APA
Nindra, U., Pal, A., Bray, V., Yip, P. Y., Tognela, A., Roberts, T. L., Becker, T. M., Williamson, J., Farzin, M., Li, J. J., Lea, V., Hagelamin, A., Ng, W., Wang, B., Lee, C. S., & Chua, W. (2024). Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer. Internal Medicine Journal. https://doi.org/10.1111/imj.16224
Vancouver
Nindra U, Pal A, Bray V, Yip PY, Tognela A, Roberts TL, et al. Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer. Internal Medicine Journal. 2024. doi:10.1111/imj.16224
BibTeX
@article{Nindra2024,
author = {Nindra, Udit and Pal, Abhijit and Bray, Victoria and Yip, Po Y and Tognela, Annette and Roberts, Tara L and Becker, Therese M and Williamson, Jonathon and Farzin, Mahtab and Li, Jing J and Lea, Vivienne and Hagelamin, Abeer and Ng, Weng and Wang, Bin and Lee, C Soon and Chua, Wei},
title = {Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16224}
}
EUVIMED